Optic Neuropathy - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Optic Neuropathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H2 2016', provides an overview of the Optic Neuropathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
- The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Optic Neuropathy Overview 7
Therapeutics Development 8
Pipeline Products for Optic Neuropathy - Overview 8
Pipeline Products for Optic Neuropathy - Comparative Analysis 9
Optic Neuropathy - Therapeutics under Development by Companies 10
Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes 11
Optic Neuropathy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Optic Neuropathy - Products under Development by Companies 15
Optic Neuropathy - Products under Investigation by Universities/Institutes 16
Optic Neuropathy - Companies Involved in Therapeutics Development 17
Amgen Inc. 17
BioAxone BioSciences, Inc. 18
Inotek Pharmaceuticals Corporation 19
Ironwood Pharmaceuticals, Inc. 20
PharmatrophiX, Inc. 21
Quark Pharmaceuticals, Inc. 22
Regenera Pharma Ltd. 23
Optic Neuropathy - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
BA-240 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
IWP-953 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
LM-22A4 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
NT-501 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
QPI-1007 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
RPh-201 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
trabodenoson - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
WSTB-1 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Optic Neuropathy - Dormant Projects 54
Optic Neuropathy - Product Development Milestones 55
Featured News & Press Releases 55
Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant 55
Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India 55
Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 56
Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications 56
Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION 57
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy 57
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Optic Neuropathy, H2 2016 8
Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Optic Neuropathy - Pipeline by Amgen Inc., H2 2016 17
Optic Neuropathy - Pipeline by BioAxone BioSciences, Inc., H2 2016 18
Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 19
Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 20
Optic Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2016 21
Optic Neuropathy - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 22
Optic Neuropathy - Pipeline by Regenera Pharma Ltd., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Optic Neuropathy - Dormant Projects, H2 2016 54